ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2025. “We continue to focus on driving commercial progress while advancing a robust portfolio of technologies through regulatory and development milestones,” said David Fischel, Chairman and CEO. “This is an exciting milestone-rich period in which we are demonstratin ...

Core Viewpoint - Intuitive Surgical's stock has declined approximately 20% over the past three months, primarily due to management's comments regarding tariff and international market pressures, despite the underlying strength of the core business [1][2][4]. Company Performance - In Q2, Intuitive Surgical reported a revenue increase of 21% to $2.44 billion, with worldwide da Vinci procedures rising about 17% [9]. - The company placed 395 da Vinci surgical systems during the quarter, contributing to an installed base of 10,488 units [9]. - Non-GAAP earnings per share (EPS) increased to $2.19 from $1.78 a year ago, indicating strong financial performance [9]. Management Insights - Management highlighted that demand in Japan was previously boosted by COVID-related funds, and several international markets are now facing budget constraints [4]. - Pricing pressure in China and rising domestic competition were also noted as potential challenges that could affect demand and system orders [4]. - To address tighter budgets, the company plans to increase reliance on leasing in international markets, where leasing currently accounts for only 30% to 40% of placements [5]. Market Conditions - Tariffs have been identified as a concern, with management estimating a gross-margin headwind of approximately 1 percentage point from tariffs in 2025, with potential for a higher impact next year [6][7]. - Despite the recent stock pullback, the company is viewed as having a resilient growth trajectory, supported by procedure growth and an expanding installed base [8][11]. Investment Considerations - The valuation of Intuitive Surgical remains premium, trading near 50 times an annualized run-rate of Q2 non-GAAP EPS, which is considered reasonable for a market leader with strong growth [12]. - The investment case is supported by procedure growth, an expanding installed base, and the rollout of higher-value platforms, which are critical for sustaining growth [11]. - Management's conservative approach and consistent risk highlighting have built credibility, suggesting that current market conditions may present a buying opportunity for long-term investors [13].

Core Points - Johnson & Johnson (J&J) entered a multibillion-dollar contract with ChemImage in 2019 to develop AI-powered surgical imaging technology [1][4] - ChemImage has filed a $1.5 billion breach of contract lawsuit against J&J, claiming the healthcare giant failed to uphold its commitments [2][3] - The trial will determine if J&J terminated the contract "with cause" or "without cause," impacting potential damages owed to ChemImage [5][6] Group 1: Contract Details - The contract included a $7 million upfront payment and outlined a potential total of $1.5 billion in royalties based on future milestones [4] - ChemImage alleges that J&J's decision to terminate the contract has harmed its business and technology development [3][4] Group 2: Legal Proceedings - The trial is presided over by US District Judge Jesse Furman, with ChemImage seeking $180 million in penalties and overdue payments [2] - J&J will argue that ChemImage failed to meet developmental milestones, justifying the contract termination [7] - ChemImage counters that delays were due to J&J's own technological issues and lack of engagement [8] Group 3: Witnesses - Nine current and former J&J executives, including key figures from the MedTech division, are expected to testify [10] - ChemImage will also call its former executives, including its ex-CEO, to support its claims [10]